LIDS, NCT05276063: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) |
|
|
| Active, not recruiting | 2/3 | 90 | Europe, Canada, US | Linsitinib, Placebo | Sling Therapeutics, Inc. | Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto | 10/24 | 09/26 | | |
